Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2019.06.21
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Rela ...
PDF (206 KB)
2019.06.18
Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory <i>F ...
PDF (153 KB)
2019.06.02
Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with N ...
PDF (193 KB)
2019.06.01
Daiichi Sankyo’s Pexidartinib Demonstrated Further Improvement with Continued Treatment of Tenosyno ...
PDF (244 KB)
2019.05.31
Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EG ...
PDF (158 KB)
2019.05.15
Daiichi Sankyo Data Presentations at 2019 ASCO Annual Meeting Highlight Depth of ADC Pipeline and P ...
PDF (177 KB)
2019.05.14
Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 I ...
PDF (266 KB)
2019.05.14
FDA Oncologic Drugs Advisory Committee Votes in Favor of Daiichi Sankyo’s Pexidartinib for the Trea ...
PDF (259 KB)
2019.05.08
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response ...
PDF (181 KB)
2019.04.29
Daiichi Sankyo Announces Two Lancet Oncology Publications of Phase 1 Dose Expansion Results of [Fam ...
PDF (218 KB)
Showing 1 - 10 of 42 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...